NASDAQ:AADI - Nasdaq - US00032Q1040 - Common Stock - Currency: USD
2.05
-0.05 (-2.38%)
The current stock price of AADI is 2.05 USD. In the past month the price decreased by -24.07%. In the past year, price decreased by -5.96%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19 | 345.13B | ||
AMGN | AMGEN INC | 14.68 | 156.41B | ||
GILD | GILEAD SCIENCES INC | 13.76 | 132.82B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1756.9 | 130.98B | ||
REGN | REGENERON PHARMACEUTICALS | 13.51 | 65.46B | ||
ARGX | ARGENX SE - ADR | 339.55 | 39.39B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.24B | ||
ONC | BEIGENE LTD-ADR | N/A | 28.00B | ||
BNTX | BIONTECH SE-ADR | N/A | 25.04B | ||
NTRA | NATERA INC | N/A | 20.40B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 17.79B | ||
BIIB | BIOGEN INC | 7.35 | 17.72B |
Aadi Bioscience, Inc. operates as a clinical-stage biopharmaceutical company. The company is headquartered in Pacific Palisades, California and currently employs 53 full-time employees. The company went IPO on 2018-06-26. The firm is focused on applying technology to deliver improved precision oncology therapies for people living with difficult-to-treat cancers.
AADI BIOSCIENCE INC
17383 Sunset Avenue, Suite A250
Pacific Palisades CALIFORNIA US
CEO: Joseph Gardner
Employees: 53
Company Website: https://aadibio.com/
Investor Relations: https://ir.aadibio.com/
Phone: 14244738055
The current stock price of AADI is 2.05 USD. The price decreased by -2.38% in the last trading session.
The exchange symbol of AADI BIOSCIENCE INC is AADI and it is listed on the Nasdaq exchange.
AADI stock is listed on the Nasdaq exchange.
8 analysts have analysed AADI and the average price target is 3.06 USD. This implies a price increase of 49.27% is expected in the next year compared to the current price of 2.05. Check the AADI BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
AADI BIOSCIENCE INC (AADI) has a market capitalization of 94.85M USD. This makes AADI a Micro Cap stock.
AADI BIOSCIENCE INC (AADI) currently has 53 employees.
AADI BIOSCIENCE INC (AADI) has a support level at 1.97 and a resistance level at 2.11. Check the full technical report for a detailed analysis of AADI support and resistance levels.
The Revenue of AADI BIOSCIENCE INC (AADI) is expected to decline by -46.53% in the next year. Check the estimates tab for more information on the AADI EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
AADI does not pay a dividend.
AADI BIOSCIENCE INC (AADI) will report earnings on 2025-05-06, before the market open.
AADI BIOSCIENCE INC (AADI) does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.35).
ChartMill assigns a fundamental rating of 2 / 10 to AADI. While AADI seems to be doing ok healthwise, there are quite some concerns on its profitability.
Over the last trailing twelve months AADI reported a non-GAAP Earnings per Share(EPS) of -2.35. The EPS increased by 3.69% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -71.98% | ||
ROE | -89.57% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 48% to AADI. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of 71.14% and a revenue growth -46.53% for AADI